-
公开(公告)号：EP2710137B1
公开(公告)日：2018-09-19
申请号：EP12755115.8
申请日：2012-03-09
IPC分类号： A61K31/352 , A61K39/395 , A61P35/00
CPC分类号： A61K39/3955 , A61K31/352 , A61K31/365 , A61K38/193 , A61K38/20 , A61K38/2006 , A61K38/2013 , A61K38/204 , A61K38/21 , A61K38/212 , A61K38/217 , A61K39/0005 , A61K39/0011 , A61K39/245 , A61K39/39558 , A61K45/06 , A61K47/02 , A61K47/60 , A61K2039/505 , C07K16/30 , C12N7/00 , C12N2710/16021 , C12N2710/16034
摘要： A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.
-
公开(公告)号：EP3370755A1
公开(公告)日：2018-09-12
申请号：EP16863169.5
申请日：2016-11-07
IPC分类号： A61K38/00 , A61K39/12 , A61K39/395
CPC分类号： A61K35/17 , A61K39/0011 , A61K39/395 , A61K39/39558 , A61K48/0058 , A61K48/0066 , A61K2039/585 , C12N5/0636 , C12N2710/10032 , C12N2760/10034 , C12N2760/20234 , Y02A50/392 , Y02A50/466 , A61K2300/00
摘要： Provided herein are methods of treating cancer by activating resident memory T cells using one or more antigenic peptides.
-
33.发明公开
公开(公告)号：EP3368675A1
公开(公告)日：2018-09-05
申请号：EP16856367.4
申请日：2016-10-14
申请人： Advaxis, Inc.
发明人： PETIT, Robert , PERRY, Kyle
IPC分类号： C12N15/74 , C07K14/005 , C07K14/195 , A61K39/02 , A61K39/12 , A61K39/39 , A61K39/00
CPC分类号： A61K39/0011 , A61K35/74 , A61K39/02 , A61K39/12 , A61K39/245 , A61K39/39 , A61K2039/545 , A61K2039/572 , A61P35/00 , C07K14/195 , C07K2319/55 , C12N2710/20022 , C12N2710/20034
摘要： The present invention provides methods of treating, protecting against, and inducing an immune response against a human papillomavirus-associated tumor or cancer, comprising the step of administering to a subject a recombinant Listeria strain expressing a construct comprising at least one human papillomavirus antigen.
-
公开(公告)号：EP3364985A1
公开(公告)日：2018-08-29
申请号：EP16858151.0
申请日：2016-10-19
发明人： CHENG, Hua
IPC分类号： A61K35/15 , A61K39/395 , C07K14/54 , C07K16/24 , A61P35/02 , A61P31/14 , C12N5/0784 , C12N15/62 , C12N15/86
CPC分类号： C12N5/0639 , A61K35/15 , A61K39/0011 , A61K39/395 , A61P35/02 , C07K14/005 , C07K14/15 , C07K14/4703 , C07K2319/00 , C12N9/1276 , C12N15/86 , C12N2740/14022 , C12N2740/16043
摘要： Provided are engineered primary blood and monocyte-derived dendritic cells, wherein the dendritic cell expresses a functional Tax protein from a T cell leukemia virus, and methods of making and using the same.
-
公开(公告)号：EP3364969A1
公开(公告)日：2018-08-29
申请号：EP16858247.6
申请日：2016-10-20
申请人： Kite Pharma, Inc. , The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
IPC分类号： A61K31/436 , C12N5/078 , C12N5/0783
CPC分类号： A61K35/17 , A61K39/0011 , A61K2039/5156 , A61K2039/5158 , A61K2039/572 , C07K14/7051 , C12N5/0636 , C12N5/0638 , C12N2501/2302 , C12N2501/2307 , C12N2501/2315 , C12N2501/727 , C12N2506/11
摘要： Provided herein are methods for delaying or inhibiting T cell maturation or differentiation in vitro for a T cell therapy, comprising contacting one or more T cells from a subject in need of a T cell therapy with an AKT inhibitor and at least one of exogenous Interleukin-7 (IL-7) and exogenous Interleukin-15 (IL-15), wherein the resulting T cells exhibit delayed maturation or differentiation. In some embodiments, the method further comprises administering the one or more T cells to a subject in need of a T cell therapy.
-
公开(公告)号：EP3363458A2
公开(公告)日：2018-08-22
申请号：EP18166281.8
申请日：2014-12-09
申请人： TARGOVAX ASA
发明人： ERIKSEN, Jon Amund
CPC分类号： A61K39/0011 , A61K35/17 , A61K2039/5158 , A61K2039/57 , A61K2039/70 , C07K14/82 , C12Q2600/156 , G01N33/483 , G01N33/505 , G01N2333/47
摘要： There is disclosed a peptide for use as a vaccine or medicament and which corresponds to a fragment of the RAS protein. The peptide comprises a region of at least 8 amino acids which includes position 13 of the RAS protein, and said region has at least 6 amino acid residues, other than at said position 13, which are identical to the corresponding region of the RAS protein. The peptide has a G13C or a G13R amino acid substitution at the amino acid corresponding to said position 13.
-
公开(公告)号：EP3362103A2
公开(公告)日：2018-08-22
申请号：EP16856074.6
申请日：2016-10-12
申请人： Nantomics, LLC
发明人： SOON-SHIONG, Patrick , BENZ, Stephen Charles , NGUYEN, Andrew , RABIZADEH, Shahrooz , NIAZI, Kayvan , BUZKO, Oleksandr , NELSON, Jay Gardner
CPC分类号： A61K39/0011
摘要： Methods and compositions for preparation and use of recombinant viruses or other recombinant expression systems are presented in which neoepitopes are first identified in a patient- and cancer-specific manner and then further filtered by HLA-match to the patient. Selected neoepitopes are then expression using sequence elements that direct the expressed neoepitope to the HLA-type (MHC-I and/or MHC-II subtype) that has desirable affinity to the filtered neoepitope.
-
公开(公告)号：EP3360873A1
公开(公告)日：2018-08-15
申请号：EP17211181.7
申请日：2009-07-07
发明人： COMBS, Andrew, P. , YUE, Eddy, W. , SPARKS, Richard, B. , ZHU, Wenyu , ZHOU, Jiacheng , LIN, Qiyan , WENG, Lingkai , YUE, Tai-Yuen , LIU, Pingli
IPC分类号： C07D413/04 , C07D413/12 , C07D271/08 , A61K31/4245 , A61K39/00 , A61K39/395
CPC分类号： A61K31/4245 , A61K39/0011 , A61K39/3955 , C07D271/08 , C07D413/04 , C07D413/12
摘要： The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
-
公开(公告)号：EP2748302B1
公开(公告)日：2018-08-15
申请号：EP12753463.4
申请日：2012-08-22
申请人： Glycotope GmbH
CPC分类号： A61K39/0216 , A61K39/0011 , A61K2039/5154 , A61K2039/585 , C07K16/1257 , C12N1/20 , C12R1/01
摘要： The present invention pertains to microorganisms of the species Bacteroides xylanisolvens expressing a core-1 antigen on their surface. These microorganisms are in particular useful for the prophylaxis and treatment of core-1 positive diseases and are particularly characterized by a stable, homogenous high core-1 expression. Also provided are pharmaceutical compositions which comprise respective core-1 positive microorganisms or fractions thereof.
-
公开(公告)号：EP3357505A1
公开(公告)日：2018-08-08
申请号：EP18164079.8
申请日：2014-12-09
申请人： TARGOVAX ASA
发明人： ERIKSEN, Jon Amund
CPC分类号： A61K39/0011 , A61K35/17 , A61K2039/5158 , A61K2039/57 , A61K2039/70 , C07K14/82 , C12Q2600/156 , G01N33/483 , G01N33/505 , G01N2333/47
摘要： There is disclosed a T-cell preparation comprising T-cells specific for a peptide when presented on an MHC molecule. The peptide corresponds to a fragment of the RAS protein and comprises a region of at least 8 amino acids which include position 12, 13 or 61 of the RAS protein. This region has at least 6 amino acid residues, other than at said position 12, 13 or 61, which are identical to the corresponding region of the RAS protein. The peptide has an amino acid substitution at the amino acid corresponding to position 12, 13 or 61 of the RAS protein.
-
-
-
-
-
-
-
-
-
搜索结果
4510 条记录 (耗时 0.037 秒)
